During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Transcript
Is HER2 an area of exploration in lung cancer?
This is a very important question, because the biomarkers for HER2 in lung cancer are a bit different than breast cancer. In lung cancer, the biomarker of response is HER2 mutations, and this is in comparison to HER2 overexpression, or FISH [fluorescence in situ hybridization], in breast cancer. HER2 mutations can occur in a subset of lung cancer and can be defined by insertions or point mutations, and they can span the HER2 gene.
Are there any novel therapies being researched in lung cancer that you have your eye on?
In lung cancer, there are several novel therapies that I think are important to know about. In the HER2 space, we do have an agent trastuzumab deruxtecan, which is showing a pretty meaningful clinical benefit with response in patients who have this aberration of HER2 mutations. We also have an approved agent in the KRAS G12C space, and I think that’s very important, as this was a previous unmet need. And then we do have emerging data for a new class of molecules known as antibody-drug conjugates, where we are seeing benefit across a number of different targets in lung cancer, including Trop-2 and HER3 as well, that may have impact for patients as well.
I think that part of the cornerstones of lung cancer are testing for molecular drivers. This is a key component, not only to have the test sent, but also wait for the test result when clinically appropriate to make treatment decisions. And I also think that the future is quite bright with novel agents that are being explored in the immune therapy space, as well as novel molecularly guided therapies as well, and also strategies to think through what we may do for patients when patients don’t have a particular molecular driver or predictive immune therapy biomarker as well.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen